Embed Size (px)
Citation preview
1
Aeon Astron Europe BV
Body Organ Biomedical Corp.
Inspired Vision
PresidentHorng-Ji Lai
再生創新醫學組織無限希望
Scaffold Platform for Innovative Biomaterial
We are the bridge to improve Life
2
Outlines
• Company profile
• Operation overview
• R & D overview
• Future development
3
Company Profile
We are the bridge to improve Life
4
Established: May 2007
Chairman: Horng-Ji Lai
Capital: NTD 465 million
Number of employees: 61(include 7 PhD)
Location: 5F, No.322, Sec 1, Neihu Rd, Neihu Dist,Taipei City 11493, Taiwan.
Laboratory & Factory Location: 3F, No.322, Sec 1, Neihu Rd, Neihu
Dist,Taipei City 11493, Taiwan.
Management philosophy:
Integrity、innovation、professionalism、passion
Corporate vision:
To build a global medical device brand, to provide patients with innovative, safe and effective medical products and treatment.
Information
LEIDEN BIO SCIENCE PARK
GLOBAL OPERATIONS CENTER_NEIHU
5
2008 2009 2010 20112012
• ologen® Collagen Matrix Launched
• FDA 510K Clearance
• Sales Cover 30 Countries• AgentschapNL Grant (EUR 0.5M)• Bio Taipei Awards: Innovation Award
(for Biocornea)AAE B.V. Established
CMDCAS Certificate
BOBC Established• ISO13485
2013
• ISO 13485• CE Certificate
SenterNovem Grant (EUR 0.3M)
• 32 Patents Filed• US invotion Patent for
Fish Scale Materials
2014 2015 2016
5 Years
• Innovatiefonds MKB+ (EUR 3M)• BOBC Listed on Taiwan Emerging
Stock Markets• Founding of the Network of
Excellence in Corneal Regeneration (NEXCR)
• 23 SCI/SCIE Publications• Technical Cooperation
with LUMC for Technology License of Biomimiq
• First 5-Year Clinical Results Announced at WOC 2014
• Obtained TGMP Certificate
• Office Relocation to Neihu Technology Park
• Clinical Trial for Biocornea in Medizinische Fakultat derUniversitat zu Koln
• Obtained certified High Tech Industry status from the Taiwan Ministry of Economic Affairs
• Aongen® Collagen Membrane Registration with the TFDA
• Obtained IRB approvals from the German BfArM and the University of Cologne to start clinical trial for ologen® Biocornea Type E.
• The ARREST BLINDNESS project Won a Horizon2020 Grant (EUR 5.99M)
2007
Milestone
6
BOBC
Aeon AstronEurope B.V.
(NL)
Aeon Ajanta India Pvt. Ltd(IN)
Aeon International B.V.(NL)
Brazil China
Aeon AstronUSA Inc.(US)
Global Reach
Planning6
7
Operation Overview
We are the bridge to improve Life
8
Core Technology and Products
Core Technology: bio scaffolds/tissue repair and Development of regenerated products
Applications
Material patentTechnology
platform
Product
Techniques of Ophthalmic Application
Biomaterials from Fish Scales
Non-specific pathogen of Procine Collagen
Biocornea Bioscleraologen® Collagen
Matrix
Techniques of Dental Application
Biomaterials from fish scales
Non-specific pathogen of Procine Collagen
Aongen ® Collagen
Matrix
Aongen ®Collagen
membrane
Collagen/Calcium
2 in 1 regeneration membrane
Note 1: 【Product】solid line: listed product，dotted line: developing product
Note 2: 【Product】sourse of material: green-specific pathogen free pig collagen,
blue-fish scale source biomaterial
9
focuses on global marketing of
branded high –level biomedical devices
Products and Services
Indication/Service
Product
Brand BOBC
Collagen
Matrix
Glaucoma,
strabismus,
pterygium,
lower conjunctival
crust excision,
corneal ulcer,
retinal
detachment
Collagen
Matrix
Gingival recession
surgery, ridgeless
area surgery, dental
implant around,
dental pulp surgery
Collagen
Membrane
Treatment of periodontal
bone defects, bone filling
of alveolar spine,
reconstruction of bone
fractures, reconstruction of
anterior alveolar spine
10
Listed Product: ologen® Collagen Matrix
EYE World First oneologen® Collagen Matrix is the world first one innovative product using in eye tissue repair
Safe and effectConciliate intraocular wound healing, avoid produce scarring physically to improve success rate in surgery
IndicationsGlaucoma, Strabismus, pterygium, reconstructive and remove scar for sub conjunctival chamber, corneal ulcer, eye surgery etc.
Strategy-Focus glaucoma surgery into eye surgery market and expand other area-Through the EU and US regulations into the market, and then toward the developing countries
-Target to become the first line of treatment products in developing countries
Clinical CaseOver 60,000 global cases up to Sep 2017
comprises:≥90% atelocollagen
;≤10%Glycosaminoglycan
porous structure and
pore diameter: 10~300 µm
1111
TargetCurrent
Product Sales and Future Key Development Areas
AAEsell more than 40 countries
AA USAthrough
Independent sales representative
richly cultivating India while
reaching out to southeast Asia
market
middle east countries
sales channel
1212
Global Reputation (I)
• ologen®Collagen Matrix
– Scientific and medical publications: 90SCI/SCIE indexed: 42
– 15 ophthalmology text books
– Presented safety and efficacy literature at eye conferences and symposiums world-wide.
– Provides continuous medical education (CME) courses on techniques, mechanism and disease algorithm world-wide.
– Major Registrations：EU CE (Class III), US FDA 510K (Class II), Canada MDL (Class IV)
12
13
R & D Overview
We are the bridge to improve Life
14
Core Technology of R&D
Natural Sources of Aquatic Creatures-
Fish Scales 、Fish skin
Bioabsorption
Highly Biocompatibility
Optimization of Material
Characteristics
Analysis of Physical- Chemical Properties in Materials
Quality Monitoring
Collagen Regeneration
Membrane
Bone Repair Filler
Biosclera BiocorneaSoft tissue
proliferation matrix
Bio-Scaffold
Purification
Medical-Grade
Collagen
Tis
sue
E
ng
ine
eri
ng
De
velo
pm
en
t o
f M
ed
ica
l M
ate
ria
lsB
iom
ate
ria
ls
15
Characteristics of Biocornea
ologen Biocornea Human cornea
Composition Type I collagen >90% Type I collagen=75%
Refractivity 1.4-1.6 1.3771
Transparency (%)(300 - 700 nm)
>90% 87-91%
Diameter (mm) 6-13 mm 10.5±0.9 mm
Oxygen permeability (DK/t) 24.95±1.7 Dk/t 6.5±0.5 Dk/t
Water content (%) 84% 78%
16
Structure of Biocornea
Human Cornea ologen Biocornea
Journal of Structural Biology 142 (2003) 327–333Progress in Retinal and Eye Research 27 (2008) 549–577
17
E Type : CE registration estimated in 2018
P Type : Initiates clinical trial in China, and US / EU
concurrently in 2019
G Type : CE and USFDA registration estimated in 2019
Ophthalmology Products Pipeline
18
New Product Development and Testing Corporative Ophthalmologists
Claus CursiefenHospital of Cologne University, Ophthalmology; NExCRChairman, Biocornea Clinician
Martine JagerNetherland Leiden University; NExCR honor chairman; ARVO former chairman; rabbit, rat experiments executor
G. P.M. Luyten Netherland Leiden University, rat experiment executor
Harminder Singh Dua University of Nottingham, Medical Guidance
Marie-Jose Tassignon Universiteit Antwerpen, Medical Guidance
Jesper Hjortdal Denmark Arhus University, executor of pig corneal
Deniz Hos University of Cologne, Germany, Biocornea Clinician
Neil Lagali Sweden Linkoping University
Stefano Ferrari Italy Veneto eye bank foundation
吳金洌Institute of Cellular and Organismic Biology, Distinguished Research Fellow
林峯輝Head of National Health Research Institute, NTU Medical Engineering professor
陳克華Taipei Veterans General Hospital, Dept. of Ophthalmology physician, organ transplant group
Global Professional Doctors and Consultant Team (2)
19
Global Partner
Hospital:：*CRO：
Distributor:
*CRO：Clinical Trial research organization
Academic Unit: Customers:
21
Global Cooperation: ARREST BLINDNESShttps://www.arrestblindness.eu/
22
Biomaterials(12 patents)
Technology Patent Strategy
US, CN, TW, JP, KR, IN, IL, BR, EU, GCC
Process for Bioscaffold(13 patents)
Application division/product
(20 patents)
US, CN, TW, EU, JP, KR, IN, IL, ID, BR
Up to Year Aug 2017, patented: 25, pending: 20
Via processing technology, designed a layered palisade transparent collagen tissue from specific parts of fish
Unique biological patent protection (invent patent)
Ophthalmology、Dental、Orthopedics, cell and tissue repair and produce regeneration bracket
Patented relevant parts of fish scale in purified manufacturing process
Product development and applications as Scaffold from fish scale major components collagen and hydroxyapatite
❖ Ophthalmology:
• Biocorena• Biological sclera
❖ Dentistry:
• Collagen Matrix• Collagen membrane• Collagen/Calcareous• two in one regeneration
membrane❖ Orthopedics:
• bone-plate ❖ Plastic surgery:
• dermal filler
23
AchievementsAwards
Subsidy
Year Item
2011 Bio Taipei Awards－Innovation Award > Bronze Medal Award
2012Industry Innovation Award in Recognition of Achievement by the Ministry of Economic Affairs：Know-How
2013Industrial Development Bureau, Ministry of Economic Affairs - Promotion Program for Commercialization of Biotechnology : EXCELLENT TECHNOLOGY(Improving the ologen® Collagen Matrix with aquatic collagen)
Item Subsidy
TWPromotion Program for Commercialization of Biotechnology (Improving the ologen® Collagen Matrix with aquatic collagen)
More than 10 million
NL
Biocornea, etc... More than 1 million
The innovation credit will support the further development of an artificial cornea made of fish scale material.
€3,000,000 (Note 1)
EUAdvanced Regenerative and REStorative Therapies to combat corneal BLINDNESS (ARREST BLINDNESS)(Horizon2020)
€5,990,000 (Note 2)
Note 1: This invoice has been paid.Note 2: We get this subsidy with other research institutions.
24
Future Development
We are the bridge to improve Life
25
Strategic Direction and Growth
User needs and Design
Research and Development
Productionand Quality
Establish world-leading medical brands
Global sales & marketing and sales
channels
RD innovative medical devices
✓ Unique biomaterial research platform✓ Specialized focus on innovative bio-
scaffolds, high-risk implantable medical devices
✓ 25 patents world wide
✓ Sales network throughout EU, US, Japan, India and other major markets.
✓ Strategic step-by-step expansion into emerging markets, increasing field sales activities
✓ Formation of key strategic business alliance in emerging markets
✓ ologen ® - ophthalmology ✓ Aongen® - dental
26
EU and US Penetration
Emerging Markets
26
Innovation and Development to Lead the WorldTaiwan to the World
27
Functional Organ
Idea
Taiwan World
Business
Tissue Defect
再生創新醫學組織無限希望
Aspired Vision
We are the bridge to improve Life
